[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oedema\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oedema":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100637869","phase-3-a-clinical-study-comparing-ankle-swelling-caused-by-two-different-blood-pressure-medications-levamlodipine-and-amlodipine-in-post-menopausal-women-with-mild-high-blood-pressure-100637869",false,"NCT07618806","A Clinical Study Comparing Ankle Swelling Caused by Two Different Blood Pressure Medications, Levamlodipine and Amlodipine, in Post-menopausal Women With Mild High Blood Pressure.","A Prospective, Multicenter, Randomized, Double-Blind, Active-Controlled Phase IIIb Clinical Trial Evaluating the Incidence of Ankle Edema (Ankle Edema Volume) Induced by Levamlodipine Monotherapy vs Amlodipine in Treatment-Naïve or Mildly Uncontrolled Hypertensive Post-Menopausal Women.","TERESA","Inclusion Criteria:\n\n1. Post-menopausal women, defined as ≥12 months of spontaneous amenorrhea, not attributable to medications or other medical conditions known to cause amenorrhea.\n2. Aged 50-79 years.\n3. Women with mild to moderate uncontrolled hypertension, defined as an SBP of 140-179 mmHg at Screening and Baseline. Patients may be treatment-naïve or previously treated with ACE inhibitors or ARBs (sartans) at Screening. Previously treated patients must discontinue prior treatment at Screening and complete a protocol-defined washout period of at least 14 days between Screening and randomization (Baseline)\\*, during which no antihypertensive treatment will be administered, ensuring that all patients start study treatment as antihypertensive monotherapy.\n\n   \\* A washout period of 14 days is required to minimize residual pharmacodynamic effects on vascular tone and edema development.\n4. Body Mass Index between 18.5 and 34.9 kg\u002Fm², inclusive, at Screening\n5. Able and willing to comprehend and sign a written informed consent form (ICF).\n\n   \\-\n\nExclusion Criteria:\n\n* 1\\. Presence of peripheral edema at screening and baseline, from any cause, including but not limited to drug-related or non-drug-related etiologies (e.g., chronic venous insufficiency, lymphedema).\n\n  2\\. Use of any CCBs, including dihydropyridine or non dihydropyridine agents (e.g., Amlodipine\u002F Levamlodipine or other CCB therapy) Known hypersensitivity, intolerance, or contraindication to dihydropyridine CCBs, including Amlodipine or Levamlodipine, or to any excipient of the investigational products.\n\n  3\\. Hypoalbuminemia, defined as serum albumin \\\u003C 3.0 g\u002FdL at Screening. 4. Clinically relevant hepatic impairment, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) values ≥ 2.5 × the site-specific upper limit of normal (ULN) at Screening or other clinically relevant severe hepatic impairment 5. Significant renal impairment, defined as estimated glomerular filtration rate (eGFR) \\\u003C 45 mL\u002Fmin at Screening.\n\n  6\\. Presence of significant cardiovascular conditions, including but not limited to:\n  * Clinically significant heart failure, defined as New York Heart Association (NYHA) Class II-IV heart failure, based on medical history, clinical evaluation, and investigator judgement. NT-proBNP values may be used as a supportive laboratory parameter in the clinical assessment of suspected heart failure but shall not be used as a stand-alone exclusion criterion in the absence of corresponding clinical signs or symptoms.\n  * Clinically relevant ischemic heart disease\n  * Clinically significant arrhythmias\n  * Conduction abnormalities of clinical relevance and uncontrolled hypertension. 7. Clinically relevant peripheral vascular disease, including:\n  * Chronic venous insufficiency with clinically significant symptoms ((CEAP ≥ C2))\n  * Other peripheral vascular conditions deemed clinically relevant by the Investigator 8. Known or suspected secondary hypertension, including but not limited to:\n  * Renal artery stenosis\n  * Endocrine causes (e.g., primary aldosteronism, pheochromocytoma, Cushing's syndrome)\n  * Other identifiable secondary causes 9. Severe hypertension at Screening, defined as SBP \\> 180 mmHg or DBP \\> 110 mmHg 10. Patients will be excluded if they are taking drugs that affect plasma volume or vasodilatory edema assessment, such as:\n  * Diuretics (thiazide, loop, potassium-sparing)\n  * SGLT2 inhibitors\n  * Systemic corticosteroids\n  * Non-study antihypertensive agents\n  * Chronic NSAIDs (except low-dose aspirin for heart protection) 11. Participation in another clinical trial within 30 days prior to Screening.","FEMALE","50 Years","79 Years",{"count":21,"type":22},344,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","High blood pressure is often treated with a medication called Amlodipine, but it can cause uncomfortable ankle swelling, especially in women. This 18-week study compares standard Amlodipine with a more purified version called Levamlodipine to see if it causes less ankle swelling while still effectively lowering blood pressure. The study is designed for post-menopausal women aged 50 to 79 with mild to moderate high blood pressure. Participants will take a daily pill and attend four clinic visits. During these visits, doctors will monitor blood pressure and carefully measure ankle volume using a simple, painless water bath method.",[28,29],"Hypertension","Oedema","NOT_YET_RECRUITING","2026-05-25",{"date":33,"type":34},"2026-06-01","ACTUAL",{"date":36,"type":22},"2026-11-30",{"date":38,"type":22},"2028-05-31",{"name":40,"class":41},"Zentiva, k.s.","INDUSTRY",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":49,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":62,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":77},"100627052","measuring-fluid-buildup-in-cancer-patients-100627052","NCT07443618","Measuring Fluid Buildup in Cancer Patients","Monitoring of Oedema in Cancer Patients - A Pilot Study","Inclusion Criteria (Outpatient breast cancer patients with lymphoedema after radiotherapy):\n\n* Habile\n* Must be able to speak and read Danish\n* Has received\u002Fis receiving radiotherapy due to breast cancer within the last 6 months\n* Is being followed in the Oncology Outpatient Clinic at Aalborg University Hospital\n* Age ≥ 18 years\n* Visible lymphoedema in at least one upper extremity\n\nInclusion Criteria (Hospitalized cancer patients with peripheral oedema in one or both lower extremities after chemotherapy):\n\n* Habile\n* Must be able to speak and read Danish\n* Has received\u002Fis receiving chemotherapy due to cancer within the last 2 months\n* Hospitalised in the Oncology Ward at Aalborg University Hospital\n* Estimated length of hospital stay of at least 6 days\n* Age ≥ 18 years\n* Visible peripheral oedema in at least one lower extremity\n\nExclusion Criteria (both groups):\n\n* Pregnant or breastfeeding women\n* Amputated limb(s)\n* Pacemaker or implanted cardioverter-defibrillator due to risk of interference from the electrical signal\n* Metallic prostheses due to risk of interference with the device signal\n* Inability to lie still for the duration of the measurement interval (minimum 2 minutes at a time)\n* Inability to stand on a scale, i.e. permanently bedridden.\n* Inability to cooperate with urine collection\n* Receiving dialysis\n* Terminal illness","ALL","18 Years",{"count":52,"type":22},46,"OBSERVATIONAL","The goal of this study is to improve the monitoring of fluid retention in cancer patients. The main question it aims to answer is: Can segmental bioelectrical impedance analysis be used to monitor local fluid retention (edema) in cancer patients? We will include:\n\n* Breast cancer patients with fluid and or lymph retention in one or both arms after radiotherapy (outpatients)\n* Cancer patients with fluid retention in one or both legs after chemotherapy (hospitalized)\n\nParticipants will:\n\n* Have measurements taken using bioelectrical impedance\n* Provide blood samples and 24-hour urine collection\n* Weight monitorering\n* Complete diet and fluid registration (inclusive enteral and parenteral)\n* Have clinical palpatory and measurement assessment of oedema.",[56,29,57,58,59,60,61],"Cancer","Bioelectrical Impedance","Lymphoedema","Chemotherapy","Radiotherapy","Fluid Balance",[63,64,65],"Localized oedema in cancer","Bioelectrical impedance","Post radiation lymphoedema","RECRUITING","2026-04-28",{"date":69,"type":34},"2026-04-29",{"date":71,"type":34},"2026-02-01",{"date":73,"type":22},"2026-07-31",{"name":75,"class":76},"Jens Rikardt Andersen","OTHER",1,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":49,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":23,"phases":90,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":4},"100625797","focused-echocardiography-for-primary-care-physicians-100625797","NCT07427303","Focused Echocardiography for Primary Care Physicians","CLINICAL FEASIBILITY OF ULTRAPORTABLE CARDIAC ULTRASOUND PERFORMED IN THE GENERAL PRACTITIONER'S OFFICE TO IDENTIFY CARDIOVASCULAR ABNORMALITIES","UPCOMING","Inclusion Criteria:\n\n* Men and women aged 65 or older with no cardiac symptoms and presenting with a treated or untreated cardiovascular risk factor (hypertension and\u002For diabetes and\u002For dyslipidemia) or\n* Adult men and women presenting with one of the following signs:\n\n  * Stage I-II exertional dyspnea\n  * Lower limb edema\n  * Unexplained fatigue\n  * Weight gain\n  * Unexplained cough\n  * History of carpal tunnel surgery (search for signs of myocardial infiltration by cardiac amyloidosis)\n\nExclusion Criteria:\n\n* Patients with arrhythmia or ventricular or supraventricular hyper excitability.\n* Symptomatic patients:\n\n  * exertional dyspnea (NYHA \\>2)\n  * palpitations\n  * malaise\n  * chest pain\n* Obese individuals with a BMI \\>35\n* Patients with breast implants\n* Patients under guardianship, conservatorship, or legal protection\n* Patients without health insurance coverage or equivalent\n* Patients known to have heart disease\n* Patients who have had a cardiology consultation within the last 5 years\n* Subjects with known heart disease, whether monitored or not.\n* Known valvular heart disease (whether monitored or not)\n* Known coronary artery disease (whether monitored or not)","65 Years","120 Years",{"count":89,"type":22},300,[91],"NA","Our society is characterized by a steady improvement in the standard of living of its inhabitants, which is reflected, among other things, in improved healthcare and quality of life (longer life expectancy, lower infant mortality, treatment of chronic diseases, cancer plan). Many factors contribute to this, but technological innovations and therapeutic advances are the main ones. This positive overall picture should not obscure the fact that there are significant regional disparities.\n\nFor more than 15 years, the former Lower Normandy region (Calvados, Manche, and Orne), like many other regions in France, has been marked by increasingly complex access to healthcare, whether for primary care or for so-called specialty disciplines. This situation is gradually leading to the creation of medical deserts. There are many reasons for this (numerus clausus, sociological changes, urbanization of young practitioners, attraction of small rural towns by medium-sized cities), which are chronic and have no clearly identified solution.\n\nThis situation complicates patient care and, in some cases, represents a major public health challenge, such as in the treatment of heart failure (HF), which affects more than one million people in France, or 2.3% of the adult population. For 2.3 times more deaths each year than strokes and five times more than myocardial infarctions.\n\nSome healthcare innovations can reduce the consequences of these areas of stress. In the field of cardiology, recent initiatives based on the creation of specialized cardiology and telemedicine care teams have been proposed. In primary care, point-of-care solutions enable many tests to be performed on an outpatient basis. Imaging plays a central role in patient care, and ultrasound is often the first-line modality in cardiology. Technological innovations in this field have made it possible to miniaturize ultrasound machines to such an extent that some of them can now be considered POCUS (point-of-care ultrasound). Their reduced manufacturing costs, combined with the maturity of the technique, make it possible to offer simplified acquisition protocols adapted to specific questions, known as targeted clinical ultrasound.\n\nThis simplification\u002Fminiaturization of ultrasound equipment has facilitated the spread of this technique outside the field of cardiology and now allows for its use by general practitioners close to patients, specifically for screening purposes. Many diseases would benefit from early screening in order to reduce hospitalizations, mortality, and societal costs. In cardiology, this approach remains difficult because the majority of patients admitted to healthcare facilities have already developed the disease. HF is characterized by an initial silent phase which, if left untreated, inevitably leads to complications and death. It is responsible for 200,000 hospitalizations per year in France, causing the deaths of 70,000 people. Certain signs, grouped under the French acronym EPOF, appear early on and can be warning signs, but they are often vague and unfamiliar to the general public. This fact is well illustrated by the results of a survey conducted by the Heart Failure and Cardiomyopathy Group (GICC) of the French Society of Cardiology (SFC) in 2017 (5,000 subjects representative of the French population aged 18 to 80). This survey noted that two-thirds of subjects presenting four of these signs (EPOF) had not consulted a cardiologist in the 12 months prior to the questionnaire. In the majority of cases, these patients, whether asymptomatic or paucisymptomatic (EPOF), have morphological and functional abnormalities of the heart, which are the first step toward more severe complications and can be detected by cardiac echocardiography.\n\nThere is currently a favorable alignment between echocardiography as a public health need (early detection of conditions that can lead to heart failure) and frontline practitioners (general practitioners). This alignment could lead to the definition of new practices and a new care pathway. While echocardiography is technically feasible in a general practitioner's office, its implementation remains to be evaluated (HAS report). This report emphasizes the lack of data in the literature to identify use cases and clinical impact in general medicine in France.",[94,95,96,29,97,98,99],"Age 65 and Older","Cardiac Risk Factors","Dyspnea; Cardiac","Fatigability","Cough","Weight Gain","2026-02-16",{"date":102,"type":34},"2026-02-23",{"date":104,"type":22},"2026-03-01",{"date":106,"type":22},"2027-05-31",{"name":108,"class":76},"University Hospital, Caen"]